I initiated this thread by focusing on lenzilumab's strong binding affinity and slow off-rate. I think Ivermectin can be a useful therapeutic against covid (it seems to actually bind the covid spike protein), instead of binding GM-CSF. But it seems that as soon as Ivermectin is ceased, all the symptoms patients were suffering come roaring back. It's just an issue I would like to know more about, if regulators continue to keep lenzilumab on the shelf.
Additionally, there is an issue regarding significantly reduced energy levels. That affects me, and I've got a couple acres of land I've got to maintain this spring. I thought it was my being lazy, progressing to just becoming lazier. But this is now ridiculous, and even somewhat debilitating. That's another reason I want to look into this subject. I had already practically self-diagnosed myself as having Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Symptoms can include problems thinking and concentrating, which I try to alleviate with staying engaged here (just don't make me read another 10-Q, or anything else from a bankruptcy court filing), and practically becoming house-bound (but I've always been a homebody).
Anyway, thank you for letting me know that Humanigen doesn't own the lenz IP. I don't anticipate that will adversely impact the safety and efficacy of lenz. Nor do I think it will result in one less short share being recalled. When that happens, I might even get to enjoy a curative dose of adrenaline!
